Neumora Shares Dive as Depression Drug Fails Phase 3 Trial
Neumora Therapeutics shares nosedived after its promising depression drug failed in a crucial Phase 3 trial, impacting investor confidence. Learn more about the implications.
Topic
biotech news
A collection of 3 issues
Neumora Therapeutics Shares Plummet 80% After Drug Trial Failure
Neumora Therapeutics stock plummets 80% to $2.05 after pivotal Phase 3 trial of their depression drug fails, impacting investor confidence.
Neumora Therapeutics Faces 80% Stock Plunge After Drug Trial Setback
Neumora Therapeutics' navacaprant fails Phase 3 trial endpoints, causing an 80% stock value drop. Discover the impact of this significant biotech setback.